Pharmacophore modelling and molecular dynamics simulation to identify novel molecules targeting catechol-O-methyltransferase and dopamine D3 receptor to combat Parkinson’s disease

Parkinson’s disease is a neurological illness that slowly impairs a small number of neurons in the substantia nigra, a part of the brain. Dopamine, a substance (neurotransmitter) that disseminates signals to different regions of the brain and, when it functions correctly, coordinates smooth and bala...

Full description

Saved in:

Bibliographic Details
Published in:	Polymer bulletin (Berlin, Germany) Vol. 81; no. 9; pp. 7893 - 7917
Main Authors:	Joy, Amitha, Menon, Sidharth, Thomas, Neethu Mariam, Christy, Meha, Menon, Aiswarya D., John, Arun
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2024 Springer Nature B.V
Subjects:	Affinity Antipsychotics Benzaldehyde Binding Brain Catechol Characterization and Evaluation of Materials Chemistry Chemistry and Materials Science Complex Fluids and Microfluidics Dopamine Dynamic stability Ligands Molecular dynamics Neurons Organic Chemistry Original Paper Parkinson's disease Physical Chemistry Polymer Sciences Proteins Psychotropic drugs Receptors Signs and symptoms Soft and Granular Matter Docking Molecular dynamics simulation Pharmacophore Parkinson’s
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Parkinson’s disease is a neurological illness that slowly impairs a small number of neurons in the substantia nigra, a part of the brain. Dopamine, a substance (neurotransmitter) that disseminates signals to different regions of the brain and, when it functions correctly, coordinates smooth and balanced muscular activity, is typically produced by these cells. One-hand tremor is frequently the first sign of Parkinson’s disease. Loss of balance, stiffness, and delayed mobility are further symptoms. Proteins including catechol-O-methyltransferase and dopamine D3 receptors were taken into consideration as prospective therapeutic targets in this study. Two ligand-based pharmacophore models were generated with the help of compounds used for Parkinson’s disease which have structural similarity, screened from the first 16 compounds found in the drug bank. In the second case, 9 compounds that have similar structure to the compound istradefylline were selected. Based on docking score, intermolecular interactions, ADME (absorption, distribution, metabolism, and excretion) features, pharmacophore, and toxicity investigations, the inhibitors among the chosen compounds were found. Additionally, the chosen inhibitor underwent a 100 nanosecond molecular dynamics simulation with the two protein targets to determine its stability and binding affinity. The compound 3,4-Bis(1,3,5,6-heptatetraenyloxy) benzaldehyde was identified to be the most promising lead molecule in this analysis due to its better binding affinity, better pharmacophore properties, and greater stability. Hence, by targeting both specified proteins, the compound 3,4-Bis(1,3,5,6-heptatetraenyloxy) benzaldehyde should be beneficial against Parkinson’s disease.
ISSN:	0170-0839 1436-2449
DOI:	10.1007/s00289-023-05087-8